Compare Citius Pharmaceuticals Inc (CTXR) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Synopsys, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Synopsys, Inc. trades at $410.38 (market cap $78.68B). The key difference: Synopsys, Inc. is far larger — about 3932× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| CTXR | SNPS | |
|---|---|---|
Market Cap | $20.01M | $78.68B |
Sector | Health | Technology |
52-Week High | $1.82 | $625.80 |
52-Week Low | $0.48 | $372.33 |
Enterprise Value | $16.23M | $87.04B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
